Skip to main content

Advertisement

SpringerLink
Log in

SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives

  • Myocardial Disease (A Abbate and G Sinagra, Section Editors)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Heart failure is responsible for a significant part of diabetes-associated cardiovascular mortality and morbidity. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are novel agents approved for the treatment of diabetes mellitus; in recent clinical trials, these agents have shown a significant reduction in cardiovascular death and hospitalization secondary to heart failure.

Recent Findings

Clinical trials with specific heart failure outcomes have shown the benefit of SGLT-2 inhibitors in reducing the mortality and morbidity associated with heart failure. The guidelines for the management of diabetes mellitus recommend the preferential use of SGLT-2 inhibitors in patients with a history of cardiovascular disease.

Summary

SGLT-2 inhibitors are potential game changers in the treatment of heart failure. Guidelines for prescription of these agents help assess risk-benefit analysis and personalize treatment for maximal benefit.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Centers for Disease Control and Prevention. National Diabetes Statistics Report: estimates of diabetes and its burden in the United States. 2017. https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf. Accessed November 25, 2020.

  2. •• IDF Diabetes Atlas. 9th edition 2019. https://www.diabetesatlas.org/en/sections/worldwide-toll-of-diabetes.html. Accessed November 25, 2020. This reference shows the scope of the epidemic of type 2 diabetes mellitus.

  3. Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3:7–11.

    Article  Google Scholar 

  4. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA. 1979;241:2035–8.

    Article  CAS  Google Scholar 

  5. Preiss D, Zetterstrand S, McMurray JJ, Ostergren J, Michelson EL, Granger CB, et al. Sattar N; Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity Investigators. Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. Diabetes Care. 2009;32:915–20.

  6. Yen DC, Watson MH, Burgess LD, et al. Positive impact of continuous-flow left ventricular assist device implantation on glycemic control in patients with type 2 diabetes mellitus and advanced chronic systolic heart failure. Pharmacotherapy. 2016;36(12):1210–6.

    Article  CAS  Google Scholar 

  7. Food and Drug Administration. Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 mellitus. 2008. fda.gov/media/135936/download. Accessed November 24, 2020.

  8. Scheen AJ. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020;16(10):556–77.

    Article  Google Scholar 

  9. Bertero E, Prates Roma L, Ameri P, Maack C. Cardiac effects of SGLT2 inhibitors: the sodium hypothesis. Cardiovasc Res. 2018;114:12–8.

    Article  CAS  Google Scholar 

  10. Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab. 2018;20:479–87.

    Article  CAS  Google Scholar 

  11. Katsiki N, Triposkiadis F. Resistance to diuretics in heart failure: any role for empagliflozin? Curr Vasc Pharmacol. 2019;17(4):421–4.

    Article  CAS  Google Scholar 

  12. • Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61(10):2108–17 This study describes the possible mechanistic aspects of the cardiovascular benefit observed with SGLT-2 inhibitors.

    Article  CAS  Google Scholar 

  13. Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845–54.

  14. Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care. 2016;39:1108–14.

    Article  Google Scholar 

  15. Butler J, Hamo CE, Filippatos G, et al. The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. Eur J Heart Fail. 2017;19(11):1390–400.

    Article  CAS  Google Scholar 

  16. • Lopaschuk GD, Verma S. Empagliflozin’s fuel hypothesis: not so soon. Cell Metab. 2016;24:200–20 Findings from this study elucidate the hypothesis that ketone body oxidation may be responsible for the cardiovascular benefit associated with SGLT-2 inhibitors.

    Article  CAS  Google Scholar 

  17. Kimura I, Inoue D, Maeda T, Hara T, Ichimura A, Miyauchi S, et al. Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). Proc Natl Acad Sci U S A. 2011;108(19):8030–5.

  18. Kang S, Verma S, Teng G, et al. Direct effects of empagliflozin on extracellular matrix remodeling in human cardiac fibroblasts: novel translational clues to EMPA-REG Outcome. Can J Cardiol. 2017;33:S169.

    Article  Google Scholar 

  19. Packer M. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis. Diabetes Obes Metab. 2018;20(6):1361–6.

    Article  CAS  Google Scholar 

  20. Garvey WT, Van Gaal L, Leiter LA, Vijapurkar U, List J, Cuddihy R, et al. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism. 2018;85:32–7.

  21. Yaribeygi H, Katsiki N, Butler AE, Sahebkar A. Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys. Drug Discov Today. 2019;24(1):256–62.

    Article  CAS  Google Scholar 

  22. Packer M, Anker SD, Butler J, Filippatos G, Zannad F. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol. 2017;2(9):1025–9.

    Article  Google Scholar 

  23. Baartscheer A, Schumacher CA, Wüst RC, Fiolet JW, Stienen GJ, Coronel R, et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia. 2017;60(3):568–73.

  24. • Scheen AJ. An update on the safety of SGLT2 inhibitors. Expert Opin Drug Saf. 2019;18(4):295–311 This study reviews and analyzes the safety data with the use of SGLT-2 inhibitors.

    Article  CAS  Google Scholar 

  25. Nyirjesy P, Sobel JD, Fung A, Mayer C, Capuano G, Ways K, et al. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin. 2014;30(6):1109–19.

  26. Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complicat. 2013;27(5):479–84.

    Article  Google Scholar 

  27. Arakaki RF. Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes. Postgrad Med. 2016;128(4):409–17.

    Article  Google Scholar 

  28. Thong KY, Yadagiri M, Barnes DJ, Morris DS, Chowdhury TA, Chuah LL, et al. Ryder REJ; ABCD Nationwide Dapagliflozin Audit contributors. Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter 2 inhibitor treatment: the ABCD nationwide dapagliflozin audit. Prim Care Diabetes. 2018;12(1):45–50.

  29. McGill JB, Subramanian S. Safety of sodium-glucose co-transporter 2 inhibitors. Am J Cardiol. 2019;124 Suppl 1:S45–52.

    Article  Google Scholar 

  30. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1687–93.

    Article  CAS  Google Scholar 

  31. Handelsman Y, Henry RR, Bloomgarden ZT, Dagogo-Jack S, DeFronzo RA, Einhorn D, et al. American Association Of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract. 2016;22(6):753–62.

  32. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.

  33. • Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28 Findings from this study demonstrated the cardiovascular benefit of empagliflozin.

  34. • Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57 Findings from this study demonstrated the cardiovascular benefit of dapagliflozin.

  35. • Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Mahaffey KW; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306 Findings from this study demonstrated the cardiovascular and renal benefits of canagliflozin.

  36. • Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. VERTIS CV Investigators. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425–35 Findings from this study demonstrated the cardiovascular benefit of canagliflozin.

  37. Ryan PB, Buse JB, Schuemie MJ, DeFalco F, Yuan Z, Stang PE, et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: a real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes Metab. 2018;20(11):2585–97.

  38. Khouri C, Cracowski JL, Roustit M. SGLT-2 inhibitors and the risk of lower-limb amputation: is this a class effect? Diabetes Obes Metab. 2018;20(6):1531–4.

    Article  CAS  Google Scholar 

  39. Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. Ann Intern Med. 2019;170(11):764–9.

    Article  Google Scholar 

  40. Scheen AJ. SGLT2 inhibitors: benefit/risk balance. Curr Diab Rep. 2016;16(10):92.

    Article  Google Scholar 

  41. U.S. Food and Drug Administration. FDA briefing document, NDA 202293 dapagliflozin tablets, 5 and 10 mg. Advisory Committee Meeting, 2011, http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm262994.pdf. Accessed on November 28 2020.

  42. Lin HW, Tseng CH. A review on the relationship between SGLT2 inhibitors and cancer. Int J Endocrinol. 2014;2014:719578.

    PubMed  PubMed Central  Google Scholar 

  43. Mishriky BM, Powell JR, Wittwer JA, Chu JX, Sewell KA, Wu Q, et al. Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis. Diabetes Obes Metab. 2019;21(10):2274–83.

  44. •• McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008 Findings from this study demonstrated the cardiovascular benefit of dapagliflozin in patients with established heart failure.

  45. •• Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F; EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413–24. https://doi.org/10.1056/NEJMoa2022190Findings from this study demonstrated the cardiovascular benefit of empagliflozin in patients with established heart failure.

  46. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Verma S, Lapuerta P, Pitt B; SOLOIST-WHF Trial Investigators Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2020.

  47. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S98–S110.

    Article  Google Scholar 

  48. Cosentino F, Grant P, Aboyans V, Bailey C, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2020;41(2):255–323.

Download references

Author information

Authors and Affiliations

  1. Endocrinology, Metabolism and Diabetes, Dept. of Internal Medicine, University of Mississippi Medical Center, Jackson, MS, USA

    Vishnu Vardhan Garla & Lillian F. Lien

  2. Mississippi Center for Clinical and Translational Research, University of Mississippi Medical Center, Jackson, MS, USA

    Vishnu Vardhan Garla

  3. Jackson, USA

    Vishnu Vardhan Garla

  4. Dept. of Internal Medicine, University of Mississippi Medical Center, Jackson, MS, USA

    Javed Butler

Authors
  1. Vishnu Vardhan Garla
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Javed Butler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lillian F. Lien
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vishnu Vardhan Garla.

Ethics declarations

Conflict of Interest

V. Garla declares no conflict of interest.

J. Butler reports being a consultant for Abbott, Adrenomed, Amgen, Applied Therapeutics, Array, AstraZeneca, Bayer, Boehringer Ingelheim, CVRx, G3 Pharma, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, NovoNordisk, Relypsa, Sequana Medical, V-Wave Limited, and Vifor, outside the submitted work.

L. F. Lien reports other from Merck, Eli Lilly and Company, Sanofi-Aventis, and Tandem, outside the submitted work. She is also Editor/Author of a textbook (Lien LF, Cox ME, Feinglos MN, Corsino L. (eds.) Glycemic Control in the Hospitalized Patient, First Edition. New York: Springer, 2010), and she receives royalties from Springer.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Myocardial Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Garla, V.V., Butler, J. & Lien, L.F. SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives. Curr Cardiol Rep 23, 59 (2021). https://doi.org/10.1007/s11886-021-01486-3

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11886-021-01486-3

Keywords

Search

Navigation